Aligos Therapeutics (ALGS) Income towards Parent Company (2019 - 2026)

Aligos Therapeutics (ALGS) has 8 years of Income towards Parent Company data on file, last reported at -$23.0 million in Q1 2026.

• Quarterly Income towards Parent Company fell 153.47% year-over-year to -$23.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$90.3 million (down 69.59% YoY) and the FY2025 annual result came in at -$24.2 million, up 81.56% from the prior year.
• Income towards Parent Company fell to -$23.0 million in Q1 2026, from -$19.9 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $43.1 million in Q1 2025 to a low of -$82.1 million in Q4 2024.
• A 5-year average of -$21.3 million and a median of -$19.9 million in 2022 frame the typical range for Income towards Parent Company.
• The widest YoY moves for Income towards Parent Company: up 223.59% in 2025, down 413.44% in 2025.
• Tracing ALGS's Income towards Parent Company over 5 years: stood at -$21.9 million in 2022, then retreated by 27.44% to -$27.9 million in 2023, then tumbled by 194.53% to -$82.1 million in 2024, then surged by 75.8% to -$19.9 million in 2025, then slipped by 15.89% to -$23.0 million in 2026.
• The last three Income towards Parent Company figures came in at -$23.0 million (Q1 2026), -$19.9 million (Q4 2025), and -$31.5 million (Q3 2025), per Business Quant data.